Lee Byung Cheol, Kim Myun Soo, Choi Sang Ho, Kim Kwang Yoon, Kim Tae Sung
School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Republic of Korea.
Int J Mol Med. 2009 Sep;24(3):327-33. doi: 10.3892/ijmm_00000236.
Vibrio vulnificus is a Gram-negative bacterium that induces severely rapid pathological progress. In this study, we evaluated the antibacterial activity of two water-soluble chitosan oligosaccharides, COS A (MW, 10,000 Da) and COS B (MW, 1,000 Da), from 90-95% deacetylated chitosan, against V. vulnificus in vitro and in vivo. Treatment with COS A resulted in significantly higher suppressive effects on the growth of V. vulnificus than treatment with COS B. The growth of V. vulnificus was inhibited within 1 h of treatment with water-soluble COS A in concentrations ranging from 0.5 to 10 mg/ml. Additionally, treatment with COS A completely inhibited V. vulnificus-induced cytotoxicity in human intestinal epithelial INT-407 cells, while COS B did not. Furthermore, the administration of COS A (0.1-0.5 mg per mouse) significantly increased the survival period of V. vulnificus-infected mice. The number of viable V. vulnificus in the spleen, liver, small intestine, and blood was significantly lower in COS A-treated mice than in untreated mice. Here, we clearly demonstrate that COS A is a potential agent for the prevention and treatment of infection with V. vulnificus.
创伤弧菌是一种革兰氏阴性菌,可引发严重且快速的病理进展。在本研究中,我们评估了两种由90 - 95%脱乙酰壳多糖制备的水溶性壳寡糖,即COS A(分子量10,000 Da)和COS B(分子量1,000 Da),在体外和体内对创伤弧菌的抗菌活性。与COS B处理相比,COS A处理对创伤弧菌生长的抑制作用显著更高。在浓度范围为0.5至10 mg/ml的水溶性COS A处理1小时内,创伤弧菌的生长受到抑制。此外,COS A处理完全抑制了创伤弧菌在人肠上皮INT - 407细胞中诱导的细胞毒性,而COS B则没有。此外,给予COS A(每只小鼠0.1 - 0.5 mg)显著延长了创伤弧菌感染小鼠的存活期。COS A处理的小鼠脾脏、肝脏、小肠和血液中活的创伤弧菌数量明显低于未处理的小鼠。在此,我们明确证明COS A是预防和治疗创伤弧菌感染的潜在药物。